Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Please include the distribution list on file.
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 03, 2023 12:00 ET
|
Medicenna Therapeutics Corp.
Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics ...
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
October 27, 2023 07:55 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
October 25, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to...
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
October 24, 2023 07:15 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
October 10, 2023 07:07 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
October 03, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signallingMDNA223...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
September 28, 2023 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
September 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...